Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD relaxes restrictions on flunixin
"Flunixin is a unique medicine in managing pain and sepsis in horses with colic."
Short-term access restored for non-food producing horses 

The Veterinary Medicines Directorate (VMD) has temporarily relaxed the restrictions that were recently imposed on the equine painkiller flunixin.

VMD has allowed the release of stock from manufacturers, which will restore short-term access to this medicine, for use in non-food producing horses.

Medicines for food-producing animals that contain the excipient diethanolamine (DEA) were recently suspended by the VMD. The decision was made following a scientific opinion from the European Medicines Agency, which highlighted concerns that there may be a risk to humans.

Among other products, flunixin 50mg/ml solution for injection was suspended, prompting concern among vets about the potential future lack of this drug for intravenous use in non-food producing horses. VMD said it is investigating potential ways to maintain the availability of injectable flunixin for use in these horses.

Commenting on the relaxation of the restrictions, BEVA president Jon Pycock said: “It remains a concern to BEVA that this mechanism was not put in place before the suspension of flunixin was imposed.

“Contrary to assertions by the VMD, wholesalers were unable to meet the demands of the veterinary profession and clinical use of this medicine was disrupted within 24 hours of the VMD’s initial announcement.

“We are surprised by the Regulator’s lack of awareness of availability in the supply chain and question why there was no consultation with the veterinary sector before the suspension was enacted. The VMD has been aware of this issue since March 2018 and it appears that no contingency was put in place to consider the animal welfare impact of this decision until it was too late.”

Tim Mair, BEVA junior vice president and specialist in equine surgery added: “Flunixin is a unique medicine in managing pain and sepsis in horses with colic. The VMD appeared to believe that this medicine could be substituted for other veterinary medicines and this is simply not the case.

“The release of stock from manufacturers is a short-term solution and, looking forward, we would like assurances that the VMD will fast track applications for the modification of product licenses to ensure that equine vets have continued access to these products.”

Stocks of flunixin held by manufacturers will be distributed with a caution letter, which explains the restricted use of the product.

BEVA is reminding all equine vets to check the horse’s food chain status when using the product - either by examining the paper passport or the recently launched chip checker on the Central Equine Database website.

Become a member or log in to add this story to your CPD history

Webinar to explore history of KC breed registers

News Story 1
 A free webinar exploring the development of the Kennel Club's registration system and the evolution of closed breed registers has been announced.

Hosted by Dr Alison Skipper, veterinary and research advisor at the Kennel Club, the webinar will delve into the development of the registry and how the changing landscape of scientific knowledge has shaped breeding practices. It will also look at what this means for the future of pedigree dogs.

The session will culminate with a look at The Kennel Club's ongoing and future engagement in this area, with a chance for attendees to put forward their thoughts and questions for discussion.

This event takes place on Microsoft Teams on Tuesday, 10 June at 7pm. To learn more, visit events.teams.microsoft.com  

Click here for more...
News Shorts
UK's BSE risk status downgraded

The WOAH has downgraded the UK's international risk status for BSE to 'negligible'.

Defra says that the UK's improved risk status recognises the reputation for having the highest standards for biosecurity. It adds that it demonstrates decades of rigorous animal control.

Outbreaks of Bovine Spongiform Encephalopathy, also known as mad cow disease, have previously resulted in bans on Britain's beef exports.

The UK's new status could lead to expanded trade and better confidence in British beef.

Christine Middlemiss, the UK's chief veterinary officer, said: "WOAH's recognition of the UK as negligible risk for BSE is a significant milestone and is a testament to the UK's strong biosecurity measures and the hard work and vigilance of farmers and livestock keepers across the country who have all played their part in managing the spread of this disease.